HIGHLIGHTS
SUMMARY
Older adults and immunocompromised individuals from a vaccine-preventable disease. The study populations included in clinical trials, including vaccine trials, should ideally reflect disease demographics. The significant heterogeneity among high-risk individuals may pose a challenge to participant recruitment and retention in clinical trials and can affect the internal validity of the trials results. A recent study found that among COVID-19 treatment and vaccine trials conducted early in the pandemic (from October 2019 to June 2020), older adults were likely to be excluded from more than 50% of treatment trials and 100% of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.